TRCT
RAPP

Tower Research Capital (TRC)’s Rapport Therapeutics RAPP Stock Holding History

Tower Research Capital (TRC)’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Buy
3,792
+3,362
+782% +$94.6K ﹤0.01% 2050
2025
Q4 		$13K Sell
430
-626
-59% -$17.3K ﹤0.01% 3432
2025
Q3 		$31.4K Sell
1,056
-1,044
-50% -$18.6K ﹤0.01% 2899
2025
Q2 		$23.9K Buy
2,100
+1,178
+128% +$12.5K ﹤0.01% 3578
2025
Q1 		$9.25K Buy
922
+181
+24% +$2.35K ﹤0.01% 3804
2024
Q4 		$13.1K Buy
741
+484
+188% +$10.7K ﹤0.01% 3554
2024
Q3 		$5.26K Buy
+257
New +$5.52K ﹤0.01% 4301

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Tower Research Capital (TRC)'s RAPP Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Rapport Therapeutics (RAPP) stake by 782% in Q1 2026, buying an estimated $94.6K and bringing the position to 3,792 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #2050.

Tower Research Capital (TRC) first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Tower Research Capital (TRC) held 3,792 shares of Rapport Therapeutics worth $119K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,362 Rapport Therapeutics shares in Q1 2026, an estimated $94.6K.
  • Rapport Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2050 holding.
  • Tower Research Capital (TRC) first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.